BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 31869000)

  • 1. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
    Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
    Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
    Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of post-chemoradiotherapy DWI ADC
    Connor S; Sit C; Anjari M; Lei M; Guerrero-Urbano T; Szyszko T; Cook G; Bassett P; Goh V
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2323-2336. PubMed ID: 34159420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection.
    Boros A; Blanchard P; Dade A; Gorphe P; Breuskin I; Even C; Nguyen F; Deutsch E; Bidault F; Janot F; Temam S; Mirghani H; Tao Y
    Laryngoscope; 2021 Mar; 131(3):E846-E850. PubMed ID: 32833260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.
    Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Ho AS; Zumsteg ZS
    Head Neck; 2018 Jun; 40(6):1228-1236. PubMed ID: 29417700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
    Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
    JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
    Nishikawa D; Hanai N; Ozawa T; Hirakawa H; Suzuki H; Nakashima T; Hasegawa Y
    Auris Nasus Larynx; 2015 Apr; 42(2):150-5. PubMed ID: 25498333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
    Clavel S; Charron MP; Bélair M; Delouya G; Fortin B; Després P; Soulières D; Filion E; Guertin L; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):567-73. PubMed ID: 21310545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database.
    Ko HC; Chen S; Wieland AM; Yu M; Baschnagel AM; Hartig GK; Harari PM; Witek ME
    Head Neck; 2017 Nov; 39(11):2159-2170. PubMed ID: 28737019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.
    Zumsteg ZS; Luu M; Kim S; Tighiouart M; Mita A; Scher KS; Lu DJ; Shiao SL; Mallen-St Clair J; Ho AS
    Ann Oncol; 2019 Jan; 30(1):76-84. PubMed ID: 30395159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron Emission Tomography-Computed Tomography Surveillance after (Chemo)Radiotherapy in Advanced Head and Neck Squamous Cell Cancer: Beyond the PET-NECK Protocol.
    Zhou S; Rulach R; Hendry F; Stobo D; James A; Dempsey MF; Grose D; Lamb C; Schipani S; Rizwanullah M; Wilson C; Lau YC; Paterson C
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):665-673. PubMed ID: 32561027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
    Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
    Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Bulky Adenopathy in Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Carcinoma Require a Planned Post-Treatment Neck Dissection for Occult Residual Disease?
    Kim RY; Vincent AG; Shokri T; Ducic Y
    J Oral Maxillofac Surg; 2023 Feb; 81(2):248-253. PubMed ID: 36528082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection.
    Smyth JK; Deal AM; Huang B; Weissler M; Zanation A; Shores C
    Laryngoscope; 2011 Sep; 121(9):1881-7. PubMed ID: 21997727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas.
    Sakashita T; Homma A; Oridate N; Suzuki S; Hatakeyama H; Kano S; Mizumachi T; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
    Auris Nasus Larynx; 2013 Apr; 40(2):211-5. PubMed ID: 22867524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer.
    Gourin CG; Williams HT; Seabolt WN; Herdman AV; Howington JW; Terris DJ
    Laryngoscope; 2006 May; 116(5):705-10. PubMed ID: 16652075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
    Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET--guided neck management policy.
    Adams G; Porceddu SV; Pryor DI; Panizza B; Foote M; Rowan A; Burmeister B
    Head Neck; 2014 Aug; 36(8):1200-6. PubMed ID: 23893554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.